August 9, 2022

Lilly takes long view on Alzheimer’s drug as FDA starts expedited review

The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab.

Donanemab is one of several drugs in late-stage clinical testing that are aimed at a protein called amyloid beta, which accumulates in sticky plaques in the brain. Targeting this protein has been the dominant approach toward treating Alzheimer’s for decades, but has yielded a long list of failed drugs and unsuccessful studies.

Eli Lilly is a 2022 Tax Incentive awardee. This program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts.